Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
Motoo NomuraAtsushi OtsukaMichio YoshimuraYumi NonomuraYo KakuShigemi MatsumotoManabu MutoPublished in: Cancer chemotherapy and pharmacology (2018)
This study showed that concurrent immunoradiotherapy is an option for patients with metastatic melanoma after progression on nivolumab.
Keyphrases